2025-07-25 - Analysis Report
Okay, here's a report summarizing the analysis of Eli Lilly and Co (LLY), incorporating the data you provided.

## Eli Lilly and Co (LLY) Stock Analysis Report

**Ticker:** LLY
**Company Name:** Eli Lilly and Co
**Description:** A global pharmaceutical company that discovers, develops, manufactures, and markets pharmaceutical products.

### 1. Performance vs. S&P 500 (VOO)

*   **Cumulative Return (LLY):** 246.65%
*   **Cumulative Return (VOO):** 98.88%
*   **Absolute Divergence:** 146.7 (LLY outperformed VOO by 146.7 percentage points)
*   **Relative Divergence:** 51.3 (LLY's outperformance is positioned at the 51.3th percentile of its historical range compared to VOO)

This indicates that LLY has significantly outperformed the S&P 500 over the analyzed period. The relative divergence suggests that while the outperformance is substantial, it is within the historical range.

**Alpha and Beta Analysis:**

| Year       | CAGR   | MDD   | Alpha  | Beta  | Cap(B) |
|------------|--------|-------|--------|-------|--------|
| 2015-2017  | 10.0%  | 56.3% | -19.0% | 0.0   | 75.8   |
| 2016-2018  | 39.0%  | 58.6% | 21.0%  | -0.1  | 103.9  |
| 2017-2019  | 50.0%  | 58.6% | 20.0%  | 0.3   | 118.0  |
| 2018-2020  | 52.0%  | 58.6% | 33.0%  | 0.1   | 151.6  |
| 2019-2021  | 106.0% | 60.6% | 57.0%  | 0.2   | 248.0  |
| 2020-2022  | 98.0%  | 64.8% | 96.0%  | 0.2   | 328.4  |
| 2021-2023  | 133.0% | 64.8% | 115.0% | 0.3   | 523.3  |
| 2022-2024  | 150.0% | 72.2% | 124.0% | 0.2   | 693.0  |
| 2023-2025  | 100.0% | 76.8% | 49.0%  | 0.2   | 723.1  |

**Analysis:**

*   **CAGR:**  Shows consistently high compounded annual growth rates, especially in recent periods (2019-2025).
*   **MDD:** Maximum Drawdown is significant, indicating potential volatility and risk.
*   **Alpha:** Positive and generally increasing Alpha suggests the stock's returns are increasingly independent of market movements (VOO), indicating strong stock-specific performance.
*   **Beta:**  Beta values are relatively low (close to 0), indicating that LLY's price is not strongly correlated with the S&P 500's movements.
*   **Cap(B):** Shows increasing market capitalization

### 2. Recent Price Action

*   **Current Price:** 805.43
*   **Previous Close:** 798.89
*   **Change:** 0.82
*   **5-day Moving Average:** 782.93
*   **20-day Moving Average:** 782.324
*   **60-day Moving Average:** 774.7362

**Analysis:**

The current price is above all three moving averages, suggesting an upward trend. The slight increase from the previous close indicates positive, but not dramatic, momentum.

### 3. Technical Indicators and Outlook

*   **Market Risk Indicator (MRI):** 0.3274 (Low Risk)
*   **RSI:** 57.23 (Neutral - neither overbought nor oversold)
*   **PPO:** 0.1719 (Positive - suggesting a slight upward trend)
*   **Hybrid Signal:** cash_7%_Buy 90% of cash (339 shares - Safe - MRI:0.33)
*   **Recent Change in Relative Divergence (20 days):** -1.7 (Short-term Decline in outperformance)
*   **Expected Return:** 153.0% (Long-term, relative to S&P 500)

**Analysis:**

*   The Low-Risk MRI and Neutral RSI provide a moderately positive outlook.
*   The PPO supports a slight upward trend.
*   The hybrid signal suggests buying opportunity
*   The negative change in relative divergence suggests some recent underperformance compared to VOO, but the overall outperformance remains significant.
*   The high expected return indicates strong confidence in LLY's long-term growth potential relative to the broader market.
*   The `change: 0.82` is taken into consideration, so recent price change is reflecting positive movement

### 4. Recent News & Events

*   **[2025-07-21]:** Major business developments, regulatory changes, or market events impacting LLY.
*   **[2025-07-25]:** Analyst discussions on LLY's performance and outlook within industry and economic contexts.
*   **[2025-07-24]:** Notable stock volatility influenced by recent news, earnings reports, or executive actions.
*   **[2025-07-22]:** Market experts highlighting both risks and opportunities for LLY, advising monitoring of company news.

**Analysis:**

These news snippets suggest that LLY is experiencing active market attention due to significant events and performance discussions. Investors should stay informed on these developments to assess their potential impact.

### 5. Recent Earnings Analysis

| 날짜         | EPS  | 매출        |
|--------------|------|-------------|
| 2025-05-01   | 3.07 | 12.73 B$    |
| 2024-10-30   | 1.08 | 11.44 B$    |
| 2024-08-08   | 3.29 | 11.30 B$    |
| 2024-04-30   | 2.49 | 8.77 B$     |
| 2025-05-01 | 2.49 | 8.77 B$ |

**Analysis:**

*   EPS and revenue figures show considerable growth, especially in the most recent quarters. This suggests strong operational performance and market demand for LLY's products.

### 6. Financial Information

**Revenue and Profitability:**

| Quarter      | Revenue    | Profit Margin |
|--------------|------------|---------------|
| 2025-03-31   | $12.73B    | 82.53%        |
| 2024-12-31   | $13.53B    | 82.24%        |
| 2024-09-30   | $11.44B    | 81.02%        |
| 2024-06-30   | $11.30B    | 80.80%        |
| 2024-03-31   | $8.77B     | 80.91%        |

**Capital and Profitability:**

| Quarter      | Equity     | ROE    |
|--------------|------------|--------|
| 2025-03-31   | $15.76B    | 17.50% |
| 2024-12-31   | $14.19B    | 31.07% |
| 2024-09-30   | $14.24B    | 6.81%  |
| 2024-06-30   | $13.56B    | 21.88% |
| 2024-03-31   | $12.81B    | 17.51% |

**Analysis:**

*   **Revenue:** Consistent revenue growth, especially evident when comparing the earliest quarter to the most recent, indicating increasing sales and market presence.
*   **Profit Margin:** Exceptionally high and stable profit margins, consistently above 80%, reflecting strong operational efficiency and pricing power.
*   **Equity:** Steady growth in equity, suggesting that the company is accumulating value and reinvesting earnings effectively.
*   **ROE:** Fluctuating ROE values, with a notable peak in 2024-12-31, which could be due to specific one-time events or effective capital utilization during that quarter.

### 7. Summary and Conclusion

Eli Lilly and Co (LLY) demonstrates strong financial performance and significant outperformance relative to the S&P 500. The company exhibits high revenue and profit margins, growing equity, and positive long-term growth expectations. While recent news suggests potential volatility, and there's been a slight decline in recent relative outperformance, the overall outlook remains favorable. The current technical indicators provide a moderately positive signal. Given the strong fundamentals and growth prospects, LLY may be a worthwhile investment, but investors should monitor recent news and market developments closely.

